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Abstract 28 
Background. Sub-optimal treatment of cardiovascular diseases (CVD) among severe mental illness (SMI) 29 
patients may contribute to physical health disparities.  30 
Aims. To identify SMI characteristics associated with meeting CVD treatment guidelines. 31 
Design & setting. Population-based electronic health record database linkage between primary care and 32 
the sole provider of secondary mental health care services in South East London, UK 33 
Methods. Cardiovascular disease prevalence, risk factor recording and Quality and Outcomes 34 
Framework (QOF) clinical target achievement was compared among 4,056 SMI primary care patients 35 
whose records were linked to secondary health care records and 270,669 patients without SMI who 36 
were not known to secondary care psychiatric services using multivariate logistic regression modelling. 37 
Data available from secondary care records were then used to identify SMI characteristics associated 38 
with QOF clinical target achievement. 39 
Results. SMI patients with coronary heart disease and heart failure experienced reduced prescribing of 40 
betablocker and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blockers (ACEI/ARB). A 41 
diagnosis of schizophrenia, being identified with any indicator of risk or illness severity, and being 42 
prescribed with depot injectable antipsychotic medication was associated with the lowest likelihood of 43 
prescribing.  44 
 45 
Conclusions. Linking primary and secondary care data allows the identification of SMI patients most at 46 
risk of under treatment for physical health problems.  47 
 48 
How this fits in 49 
Patients with severe mental illness (SMI) experience lower life expectancy than the general population 50 
and sub-optimal treatment of cardiovascular diseases has been identified as one potential contributory 51 
factor. We find that SMI patients in South East London are under-prescribed betablockers and ACE 52 
Inhibitors/Angiotensin Receptor Blockers as secondary prevention following coronary heart disease 53 
(CHD) and heart failure (HF). Patients with schizophrenia, those prescribed depot injectable 54 
antipsychotic medication, those with more severe illness and those identified with any indicator of ‘risk’ 55 
are the least likely to be prescribed these medications following CHD and HF. This may help clinicians 56 
identify patients at greatest risk of sub-optimal treatment. 57 
 58 
 59 
Introduction 60 
Patients with severe mental illness (SMI), including schizophrenia, bipolar affective disorder, 61 
schizoaffective disorder or other non-organic psychoses, experience lower life expectancy than the 62 
general population.[1-4]This is largely attributed to common physical disorder, particularly cardiovascular 63 
diseases (CVDs)[2, 3, 5, 6]Excess mortality linked to CVDs is attributed to several factors, including elevated 64 
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risk factors such as smoking; side effects of pharmacological treatment; diagnostic overshadowing; and, 65 
sub-optimal management of co-morbid physical conditions.[7-14] Previous studies have been unable to 66 
investigate associations for varying SMI-related characteristics since data on physical health and clinical 67 
management sits mainly within primary care while mental health condition and management records 68 
are mainly stored in secondary care.  69 
We use London borough population-based data from a linkage of primary, and secondary mental health 70 
care records to: compare CVD prevalence, risk factor recording and treatment for established CVD, and 71 
primary care consultation frequency by SMI status; examine whether SMI illness characteristics are 72 
differentially associated with CVD prevalence and treatment; and, assess the impact of adjustments for 73 
consultation frequency. 74 
Methods 75 
Setting & data sources 76 
Lambeth is a diverse borough in South East London, with a greater number of Black Caribbean and Black 77 
African residents but fewer South Asian residents than other areas,[15] and is more deprived than 78 
England as a whole.[16]Pseudonymised primary care data were extracted on 31st March 2013 from 79 
computerised medical records of all except one GP practice (n=48) within Lambeth, as part of Lambeth 80 
DataNet (LDN) covering a population of 366,317 registered patients. This was a cross-sectional extract of 81 
LDN, but for some records (e.g., BP), information on all measures recorded during 31st January 2012 to 82 
31st October 2013 were collected to determine whether Quality and Outcomes Framework (QOF) (an 83 
annual reward and incentive programme detailing GP practice achievement results [17]) clinical targets 84 
had been met. Secondary care data came from the Case Register Interactive Search (CRIS),[18]an 85 
application allowing researchers access to pseudonymised electronic health record (EHR) data from the 86 
South London and Maudsley NHS Foundation Trust (SLaM). CRIS provides searchable access to de-87 
identified text (unstructured data) from the clinical record.  88 
Data linkage 89 
Data were linked and stored by the Clinical Data Linkage Service (CDLS) which provides a safe haven 90 
environment with strict governance arrangements. Data were linked using encrypted NHS numbers 91 
which were subsequently removed and destroyed, fully anonymising the linked dataset. 92 
Measures 93 
Lambeth DataNet (LDN) 94 
Data were extracted on gender, year of birth, ethnicity, and 2011-defined lower super output area 95 
(LSOA). LSOA data were used to estimate deprivation on the basis of patient area of residence using the 96 
Index of Multiple Deprivation (IMD-2010) and a conversion to 2011 LSOA values. GP clinical register data 97 
(lists established and maintained by practices of patients identified with particular clinical outcomes for 98 
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QOF purposes) were collected for heart failure (HF), coronary heart disease (CHD), hypertension (HYP) 99 
and stroke/transient ischaemic attack (STIA). Data were also collected on CVD risk factor recording, e.g., 100 
blood pressure (BP); clinical values and dates; and, mean number of primary care consultations 101 
(including GP, nurse, face-to-face, and telephone) between 2010 and 2013. A binary variable was 102 
created to distinguish median or below and above median mean annual number of consultations. 103 
 104 
Case Register Interactive Search (CRIS) 105 
Diagnostic codes for any primary or secondary diagnosis of schizophrenia, bipolar affective disorder, and 106 
schizoaffective disorder or other non-organic psychoses were extracted. An indicator of SMI severity 107 
was created coding SMI patients as 1 if they ever had a record of an inpatient stay, being treated under 108 
the Mental Health Act, difficulty managing their physical health, or contact with Assertive Outreach, 109 
Crisis or A&E liaison team (or 0 if they had not been recorded with any of these). Similarly, an indicator 110 
of risk coded SMI patients as 1/0 to indicate if they had ever been identified under the ‘violence and 111 
aggression’ subscale of risk assessment with a history of violence, non-compliance, or forensic history. 112 
Lastly, binary indicators of antipsychotic medication prescription were extracted - including binary 113 
indicators of atypical, typical, and depot injectable medication. 114 
Statistical analyses 115 
Pearson’s chi squared tests and logistic regression analyses were used to compare CVD prevalence, risk 116 
factor recording, QOF target achievement, and primary care consultation frequency by SMI status. Using 117 
linked data, comparisons by SMI status in CVD prevalence and prescribing were then examined by 118 
individual SMI characteristics. Logistic regression analyses were used to assess whether any differences 119 
in CVD prevalence or prescribing could be accounted for by adjustment for socio-demographic 120 
characteristics and consultation frequency. P-values, unadjusted and adjusted odds ratios (OR) and 95% 121 
confidence intervals (CI) are shown. Due to the large number of statistical tests conducted, we used an 122 
alpha level of p<0.01 to determine statistical significance. All analyses were conducted using STATA 123 
v12.[19] 124 
Results 125 
Data were obtained for LDN patients aged 16+ years (n=295,301); of these, 8.1% (n=23,919) were linked 126 
to secondary mental health care records. Among those with linked records, n=4056 (16.9%) were 127 
recorded with SMI by their GP in LDN. Analyses compared those with recorded SMI in primary care with 128 
linked secondary care records (n=4056) to those not recorded with SMI in primary care or linked to 129 
secondary care (n=270,669). 130 
Socio-demographics, CVD prevalence and consultation frequency among patients with and without SMI 131 
SMI status was associated with gender, age, ethnicity, deprivation, consultation frequency, and greater 132 
prevalence of CVDs (Table 1). In patients with an established CVD (data not shown) there were no longer 133 
associations between SMI status and gender, nor age among patients with CHD or STIA. SMI status was 134 
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only associated with ethnicity and GP consultation rate among HYP patients and SMI status was no 135 
longer associated with deprivation among patients with any CVD condition.  136 
Socio-demographic characteristics of SMI sub-groups 137 
The SMI characteristics extracted from secondary care data are illustrated in Table 2. Adjusting for all 138 
socio-demographic characteristics simultaneously (data not shown), being Black African, Black 139 
Caribbean, other Black and younger age was associated with indicators of risk and severity, and with 140 
receiving depot injectable antipsychotic medication; male gender was also associated with risk. Being 141 
Black Caribbean and older was associated with receipt of typical antipsychotics, while younger age and 142 
being Black African was associated with receipt of atypical antipsychotics. Relative to those with a 143 
diagnosis of schizophrenia, those diagnosed with bipolar disorder were younger, more likely to be 144 
identified as British/mixed British, female, and to consult primary care more frequently (p=0.01). Those 145 
diagnosed with schizoaffective disorder/other non-organic psychoses were younger, more likely to be 146 
female, and to consult primary care less frequently relative to schizophrenia patients (except where 147 
indicated, all p-values <0.001). 148 
CVD risk factor recording and QOF target achievement  149 
CVD risk factor recording (e.g. BP) was in general high for patients with and without SMI (Table 3). 150 
Among those with established CVDs, SMI patients were more likely to have a record of their alcohol 151 
intake. Among HYP patients, SMI status was also associated with greater recording of BMI and HbA1c 152 
levels. SMI patients with CHD were less likely to have a BP record, while those with STIA were less likely 153 
to have a record of BP and smoking status. CVD risk assessment (e.g. Framingham risk score) was 154 
significantly less common among SMI patients. Despite significantly higher prevalence of CVDs in the 155 
SMI group overall, there was little or no difference in the prevalence of co-morbid CVDs or diabetes by 156 
SMI status among those with established CVDs. Among HYP patients, diabetes was significantly more 157 
common among SMI than non-SMI patients. 158 
For most QOF targets, there was no significant difference between SMI and non-SMI patients. For SMI 159 
patients with HF and CHD, a significant shortfall was observed in prescribing with ACE inhibitors or 160 
angiotensin receptor blockers (ACEIs/ARBs) and beta-blockers. 161 
Regression analyses of QOF target achievement 162 
Regression analyses (Table 4) focussed on differences in CVD prescribing by SMI status as these 163 
differences have previously been identified as a potential contributor to excess cardiovascular mortality 164 
among SMI patients [12] and were the key differences identified in Table 3. Associations between SMI 165 
status and beta-blocker and ACEI/ARB medication among HF patients remained after accounting for 166 
both socio-demographic characteristics and consultation rates. Among CHD patients, the association 167 
between SMI status and betablocker prescription was accounted for by ethnicity but the shortfall in 168 
ACEI/ARB prescribing among CHD patients with SMI remained following adjustments.  169 
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For analyses examining SMI-subgroups associated with betablocker and ACEI/ARB prescribing, CHD and 170 
HF were combined due to small numbers (Table 5). After adjustments, prescribing of betablocker and 171 
ACEI/ARB medication among patients with CHD or HF combined was significantly lower for SMI patients 172 
overall (OR 0.48 and 0.42, respectively); and, was particularly reduced for patients ever prescribed depot 173 
injectable antipsychotic medication (OR 0.22 and 0.32, respectively), those with any indicator of risk (OR 174 
0.25 and 0.22, respectively),  those diagnosed with schizophrenia (OR 0.38 and 0.27, respectively) and 175 
those with any indicator of SMI severity (OR 0.39 and 0.31, respectively).   176 
Discussion 177 
Summary 178 
We found elevated rates of CVDs among SMI patients; however, there may be under-recording of CVD 179 
co-morbidities among SMI patients with established CVDs. Risk factor recording was high, though 180 
significant differences by SMI status were identified. Overall, QOF target achievement was not impaired 181 
in SMI patients but we found significant consistent associations between SMI status and reduced 182 
prescribing of ACEI/ARB and betablocker medication as secondary prevention of CHD and HF. SMI 183 
patients with schizophrenia, those identified with any indicator of risk or illness severity, and those ever 184 
prescribed depot injectable antipsychotics were least likely to be prescribed ACEI/ARBs and 185 
betablockers. 186 
Strengths and limitations 187 
This study makes use of a population-based data linkage between primary and secondary care records. 188 
We were able to identify patient and illness-related characteristics associated with recording and 189 
treatment of CVDs and to highlight issues warranting further investigation that may best target 190 
disparities and reduce inequalities in physical co-morbidity and mortality. The main limitation pertains 191 
to the generalisability to other geographical areas; however, our findings are in line with evidence from 192 
national and international research, and we believe that this study is proof of principle of the utility of 193 
data linkage, which could be used elsewhere to corroborate the findings. While our analyses focus on 194 
incentivised QOF targets; it is possible that discrepancies in non-QOF targets may differ.   195 
Comparison with existing literature 196 
While SMI patients were more likely to be recorded with CVDs overall, we found little evidence for 197 
elevated rates of CVD co-morbid conditions among those with established CVDs. Previous research has 198 
found no difference in the pattern of physical health co- and multi-morbidities by SMI status and lower 199 
than expected rates of certain CVDs among SMI patients given higher CVD-related mortality. [3, 21, 22] One 200 
of several explanations suggested is that this may be linked to less frequent GP consultations[21, 22]; 201 
however, we report elevated consultation rates among SMI patients overall, and among SMI patients 202 
with established CVD, in line with previous findings.[23] SMI patients were less likely to have a CVD risk 203 
assessment, and while such tools may not be as accurate for the SMI population,[24, 25]it is unclear 204 
whether this concern - or other factors accounted for this observation.  205 
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Lower than expected CVD co-morbidities may also be linked to increased CVD-related mortality, since 206 
we found that SMI patients with established CVDs were under-represented in older age groups.  We also 207 
found lower than expected differences in the proportion of Black SMI patients among those with CHD 208 
and HYP. This suggests that for these patients, either SMI status does not confer an excess risk of these 209 
outcomes; that unlike other ethnic groups, compared to those without SMI, CHD and HYP is not 210 
elevated for Black SMI patients; or, that CHD and HYP is less frequently recorded among Black SMI 211 
patients; for example, due to excess mortality.  212 
Treatment differences 213 
In line with previous findings,[7, 14, 22, 26] we found evidence for reduced prescription of ACEI/ARB and 214 
betablocker medications for CVD secondary prevention. Under-prescribing in CVDs has been previously 215 
linked with excess mortality among SMI patients[7, 12, 22, 26, 27]and therefore may  contribute to disparities 216 
in life expectancies. Reduced ACEI/ARB prescribing in CHD among SMI patients could partly reflect 217 
differences in the effectiveness of these drugs as hypotensive agents among Black Caribbean and Black 218 
African patients.[28]National Institute for Health and Care Excellence (NICE) HYP guidelines[29] indicate 219 
prescribing of ARBs rather than ACEIs among Black patients; however, the associations remained after 220 
adjustments for ethnicity and were robust when ACEIs and ARB prescriptions were analysed separately. 221 
Reduced prescribing is also unlikely linked to reduced attendance at primary care since we found greater 222 
consultation frequency among SMI patients and adjustments strengthened negative associations with 223 
prescribing. 224 
There may, however, be reluctance to prescribe certain CVD medications due to concerns about 225 
adherence. Adherence may be lower for drugs where the dose has to be up-titrated to maximally 226 
tolerated doses as for beta-blockers and ACEI/ARBs; these medications require monitoring, and thus 227 
adherence to a monitoring regime to assess for side-effects. Monitoring also involves regular blood 228 
tests; such a commitment may be perceived as too demanding for GPs assessing SMI patients, and/or 229 
SMI patients may be less willing to commit themselves to such monitoring. However, a recent US study 230 
assessing adherence in patients with and without schizophrenia found no evidence for reduced 231 
adherence to ACEI/ARB medication.[30] One reason previously suggested for reluctance to prescribe 232 
certain cardiovascular medications is the potential for harm in overdose.[14, 22] While research does not 233 
support an association between cardiovascular medication and excess suicide, [31, 32] practitioners could 234 
conceivably have concerns around correct adherence among SMI patients, for example, leading to 235 
accidental overdose. 236 
Further quantitative and qualitative work may usefully further explore these explanations. Qualitative 237 
evidence suggests that primary care physicians may view SMI patients as harder to manage [32, 33] and be 238 
less willing to intervene when cardiovascular risk factors are identified.[34] Further, there may be 239 
reluctance among SMI patients to accept prescriptions due to mistrust or lack of adequate 240 
communication between physician and patient.[35] For patients with greater illness severity, the role of 241 
secondary care physicians may be more pertinent in managing physical health. 242 
8 
 
Lastly, QOF exception rates (e.g. due to informed dissent or treatment unsuitability) are higher in SMI 243 
patients, [36, 37] potentially inflating QOF achievement. However, our analyses did not exclude exception 244 
reported patients, so our reported achievement rates were not influenced by exception reporting 245 
among SMI patients. 246 
SMI subgroups 247 
Betablocker and ACEI/ARB prescription was reduced in SMI patients with CHD or HF overall, but the 248 
reduction was greatest in SMI patients identified with any indicator of risk, prescription of depot 249 
injectable antipsychotics, schizophrenia diagnosis, and any indicator of SMI severity. While these 250 
associations have not been previously investigated to our knowledge, Laursen et al.[25]reported that 251 
rates of ‘unnatural’ deaths were elevated among patients with SMI who were not prescribed 252 
cardiovascular medication, also indicating an association with illness severity. The sub-groups identified 253 
as most at risk of under-prescribing may be those most likely to be seen as the ‘hardest to treat’ by GPs 254 
and those least likely commit to the monitoring and follow-up as implied above. Further qualitative work 255 
should explore these associations among clinicians and patients who have been identified as at risk of 256 
under-prescribing. 257 
Implications  258 
Our findings deepen the understanding of disparities in morbidity and healthcare among individuals 259 
with SMI and help to build possible explanations for these discrepancies by identifying characteristics of 260 
SMI patients associated with the lowest likelihood of optimal treatment.  Our findings underline the 261 
value of closer working between primary and secondary care in improving outcomes for SMI patients. 262 
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Table 1 Socio-demographic characteristics and CVD prevalence by severe mental illness (SMI) status  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***p<0.001 
† 
One patient recorded as sex “unknown”. SMI patients are those known to both primary and secondary care, non-
SMI patients are those known only to primary care and not registered with SMI. ‘Consultations’ refers to mean 
number of GP and nurse telephone, face-to-face and home primary care consultations per calendar year between 
2010 and 2013. 
 
  
 
Non-SMI 
(N=270,669) 
SMI 
(N=4,056) 
   n (%) n (%) p 
Sex
†
 
  
<0.001
***
 
Female 137353 (50.8) 1797 (44.3) 
 Male 133315 (49.3) 2259 (55.7) 
 Age group 
  
<0.001
***
 
16-24 32776 (12.1) 162 (4.0) 
 25-34 88062 (32.5) 678 (32.5) 
 35-44 59279 (21.9) 907 (22.4) 
 45-54 42839 (15.8) 1095 (27.0) 
 55-64 23734 (8.8) 624 (15.4) 
 65-74 14035 (5.2) 347 (8.6) 
 75+ 9944 (3.7) 243 (6.0) 
 Ethnicity  
  
<0.001
***
 
British/mixed  78332 (35.0) 1124 (31.6) 
 Irish 5253 (2.4) 104 (2.9) 
 Indian/Pakistani/Bangladeshi/mixed 16042 (7.2) 219 (6.2) 
 Caribbean/mixed  21401 (9.6) 840 (23.7) 
 African/mixed  27286 (12.2) 545 (15.3) 
 Chinese/other 10871 (4.9) 90 (2.5) 
 Other white 54080 (24.2) 373 (10.5) 
 Other black 6262 (2.8) 188 (5.3) 
 Other mixed  4254 (1.9) 69 (1.9) 
 Deprivation quintile  
 
 
<0.001
***
 
Most deprived 47162 (18.1) 1004 (25.0) 
 2 54656 (21.0) 918 (22.9) 
 3 54342 (20.9) 836 (20.8) 
 4 57149 (22.0) 713 (17.8) 
 Least deprived 47054 (18.1) 543 (13.5) 
 Consultations 
 
 
 
Mean (SD) 4.7 (4.3) 9.4 (8.0)  
Median/below  123501 (53.1) 813 (20.9) <0.001
***
 
Above median 109286 (47.0) 3074 (79.1) 
 
Cardiovascular diseases 
   Hypertension 28010 (10.4) 762 (18.8) <0.001
***
 
Coronary heart disease 4109 (1.5) 97 (2.4) <0.001
***
 
Heart Failure 1259 (0.5) 45 (1.1) <0.001
***
 
Stroke/transient ischaemic attack 2544 (0.9) 100 (2.5) <0.001
***
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Table 2 Indicators of severity and risk identified from secondary care data among patients with severe mental 
illness (SMI) 
  
SMI 
(N=4056) 
  n (%) 
Diagnosis 
 Schizophrenia 1721 (53.6) 
Bipolar affective disorder 716 (22.3) 
Other non-organic psychoses 773 (24.1) 
Indicator of severity, ever: 2147 (53.0) 
Treated under Mental Health Act 1416 (34.9) 
Inpatient 1927 (47.5) 
Seen by crisis team 23 (0.6) 
Seen by assertive outreach 11 (0.3) 
A & E outpatient episode 445 (11.0) 
Difficulty managing physical health 676 (16.7) 
Indicator of risk, ever: 1751 (43.0) 
History of non-compliance 1296 (32.0) 
History of violence 1171 (28.9) 
Forensic history 620 (15.3)  
Antipsychotics, ever: 
 Depot injectable 1112 (32.3) 
Atypical 3255 (94.5) 
Typical  1506 (43.7) 
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Table 3 CVD risk factor recording and QOF CVD target achievement by serious mental illness (SMI) status and among patients with CVD conditions. 
*p<0.05, **p<0.01, ***p<0.001. 
†
Refers to QOF guidelines 2012/13
[17]
 
1
If non-haemorrhagic (non-SMI n=2366& SMI n=94).2 If registered with MI (non-SMI n=2951 & SMI n=68). All QOF management guidelines refer to records since 
registration with outcomes. CHD= coronary heart disease, MI=myocardial infarction, HYP=hypertension, DM=diabetes mellitus, BP=blood pressure, 
ACEI/ARB=angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, TSH=thyroid stimulating hormone, EGFR=estimated glomerular filtration 
rate, BMI=body mass index, HbA1c=glycated haemoglobin test.  
2
MI drugs - "quadruple therapy" including statin, antiplatelet/anticoagulant, betablocker and ACEI/ARB prescription. 
  Heart failure (HF) Coronary heart disease (CHD) Hypertension (HYP) 
Stroke/transient ischaemic attack 
(STIA) 
 
Non-SMI 
(n=1259) SMI (n=45) 
p 
Non-SMI 
(n=4109) 
SMI 
(n=97) 
p 
Non-SMI 
(n=28010) 
SMI 
(n=762) 
p 
Non-SMI 
(n=2544) 
SMI 
(n=100) 
p Risk Factor recording n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
BP record 1251 (99.4) 44 (97.8) 0.206 4079 (99.3) 94 (96.9) 0.009** 27859 (99.5) 754 (99.0) 0.061 2519 (99.0) 96 (96.0) 0.004** 
Smoking status record 1257 (99.8) 45 (100.0) 0.789 4099 (99.8) 96 (99.0) 0.133 27977 (99.9) 759 (99.6) 0.034* 2537 (99.7) 97 (97.0) <.001*** 
HbA1c record 805 (63.9) 26 (57.8) 0.398 2728 (66.4) 67 (69.1) 0.580 16468 (58.8) 531 (69.7) <.001*** 1544 (60.7) 69 (69.0) 0.095 
Cholesterol record 1206 (95.8) 45 (100.0) 0.160 4017 (97.8) 94 (96.9) 0.576 26880 (96.0) 734 (96.3) 0.618 2441 (96.0) 94 (94.0) 0.336 
BMI record 1187 (94.3) 45 (100.0) 0.099 3849 (93.7) 94 (96.9) 0.193 26386 (94.2) 743 (97.5) <.001*** 2317 (91.1) 95 (95.0) 0.174 
Alcohol record 992 (78.8) 45 (100.0) 0.001*** 3325 (80.9) 88 (90.7) 0.015* 22637 (80.8) 716 (94.0) <.001*** 1966 (77.3) 92 (92.0) 0.001*** 
eGFR record 1229 (97.6) 44 (97.8) 0.945 3987 97.0) 94 (96.9) 0.943 26854 (95.9) 731 (95.9) 0.936 2415 (94.9) 96 (96.0) 0.631 
CVD risk factor assessment 236 (18.8) 10 (22.2) 0.558 727 (17.7) 11 (11.3) 0.104 9995 (35.6) 230 (30.2) 0.002** 460 (18.1) 14 (14.0) 0.297 
TSH record 1140 (90.6) 40 (88.9) 0.709 3619 (88.1) 85 (87.6) 0.893 23884 (85.3) 677 (88.9) 0.006** 2142 (84.2) 86 (86.0) 0.627 
CHD co-morbidity 569 (45.2) 13 (28.9) 0.031* - - - 2590 (9.3) 57 (7.5) 0.096 454 (17.9) 19 (19.0) 0.768 
DM co-morbidity 428 (34.0) 17 (37.8) 0.599 1294 (31.5) 31 (32.0) 0.922 6837 (24.4) 276 (36.2) <.001*** 647 (25.4) 36 (36.0) 0.018* 
HYP co-morbidity 886 (70.4) 27 (60.0) 0.136 2590 (63.0) 57 (58.8) 0.389 - - - 1680 (66.0) 66 (66.0) 0.994 
QOF target achievement
†
 
            Last BP record within 9 months - - - - - - 18286 (65.3) 500 (65.6) 0.849 - - - 
Normal BP (150/90) in last 9 
months - - - - - - 20829 (74.4) 557 (73.1) 0.430 1907 (75.0) 67 (67.0) 0.073 
Normal BP (150/90) in last 15 
months - - - 3451 (84.0) 80 (82.5) 0.688 - - - - - - 
Cholesterol record in last 15 months 
       
1786 (70.2) 69 (69.0) 0.796 
Cholesterol <5mmol/l in last 15 months - - 2816 (68.5) 58 (59.8) 0.067 - - - 1477 (56.9) 52 (52.0) 0.334 
Anticoagulant/antiplatelet last 15 
months - - - 3002 (73.1) 69 (71.1) 0.667 - - - 1460 (61.7) 59 (62.8) 0.840
1
 
Quadruple therapy
2
 - - - 1530 (51.9) 28 (41.2) 0.082 - - - - - - 
Betablocker 879 (69.8) 18 (40.0) <.001*** 2710 (66.0) 53 (54.6) 0.020** - - - - - - 
ACEI/ARB  1051 (83.5) 28 (62.2) <.001*** - - - - - - - - - 
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Table 4 Differences in Quality and Outcomes Framework (QOF) CVD prescribing targets† by serious mental illness 
(SMI) status adjusted for socio-demographic characteristics and primary care consultation frequency. 
  
Reference 
(non-SMI) 
Unadjusted OR     
(95% CI) 
Adjusted for socio-
demographics OR
a
 
(95% CI) 
Additionally adjusted 
for consultation rate 
OR
b
 (95% CI) 
Betablocker 
      After CHD 1.00 0.62 (0.41 - 0.93)* 0.68 (0.44 - 1.05) 0.66 (0.42 - 1.01) 
  After HF 1.00 0.29 (0.16 - 0.53)*** 0.29 (0.15 - 0.55)*** 0.27 (0.14 - 0.52)*** 
ACEI/ARB 
      After CHD  1.00 0.59 (0.36 - 0.97)* 0.55 (0.33 - 0.94)*  0.47 (0.27 - 0.80)** 
  After HF 1.00 0.33 (0.18 - 0.61)*** 0.34 (0.18 - 0.66)*** 0.31 (0.16 - 0.60)*** 
Antiplatelet/anticoagulant 
      After CHD 1.00 0.95 (0.54 - 1.65) 1.04 (0.57 - 1.89) 0.94 (0.51 - 1.73) 
  After STIA 1.00 1.04 (0.68 - 1.60) 0.99 (0.62 - 1.59) 1.04 (0.64 - 1.69) 
Statin  
       After CHD 1.00 0.76 (0.45 - 1.28) 0.78 (0.45 - 1.36) 0.70 (0.40 - 1.23) 
Quadruple therapy
1
 
    
  After CHD 1.00 0.65 (0.40 - 1.06) 0.62 (0.37 - 1.04) 0.28 (0.34 - 0.98)* 
*p<0.05, **p<0.01, ***p<0.001. 
†
Refers to QOF guidelines 2012/13
[17]
 
ACEI/ARB=angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CHD=coronary heart disease; 
HF=heart failure; 
1
Quadruple therapy indicated in patients with history of myocardial infarction and includes statin, 
antiplatelet/anticoagulant, betablocker and ACEI/ARB medication. 
a
Adjusted for age (continuous), gender, ethnicity, and borough-level deprivation;
 b
 additionally adjusted for mean 
annual number of primary consultations.
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Table 5 Serious mental illness (SMI) characteristics associated with Betablocker and ACEI/ARB prescribing among CHD/HF patients 
*p<0.05, **p<0.01, ***p<0.001. 
ACEI/ARB=angiotensin-converter enzyme inhibitor/angiotensin receptor blocker.
1
 Includes any of: ever had an inpatient stay, any record of being treated 
under the Mental Health Act, any record of difficulty managing their physical health, or any record of an Assertive Outreach/Crisis/A&E episode. 
2
Includes any 
of: recorded history of violence, recorded history of non-compliance, and any record of a forensic history. 
a
Adjusted for age (continuous), gender, ethnicity, borough-level deprivation and recorded coronary heart disease/heart failure;
 b
 additionally adjusted for 
mean annual number of primary consultations. 
 
  Betablockers if recorded with CHD or HF (n=3347) ACEI/ARB if recorded with CHD or HF (n=3760) 
  n (%) 
Unadjusted OR     (95% 
CI) 
Adjusted for socio-
demographics ORa 
(95% CI) 
Additionally adjusted 
for consultation rate 
ORb(95% CI) 
n (%) 
Unadjusted OR       
(95% CI) 
Adjusted for socio-
demographics  ORa 
(95% CI) 
Additionally adjusted 
for consultation rate 
ORb (95% CI) 
Non-SMI 3279 (68.3) 1.00 1.00 1.00 3677 (76.6) 1.00 1.00 1.00 
SMI overall 68 (52.7) 0.52 (0.36 – 0.73)*** 0.50 (0.35 – 0.73)*** 0.48 (0.33 – 0.69)*** 83 (64.3) 0.55 (0.38 – 0.79)*** 0.49 (0.34 – 0.73)*** 0.42 (0.28 – 0.62)*** 
SMI by diagnosis 
 
 
   
 
  
Schizophrenia 30 (50.0) 0.46 (0.28 - 0.77)** 0.42 (0.24 - 0.73)** 0.38 (0.22 - 0.67)*** 36 (60.0) 0.46 (0.27 - 0.77)** 0.35 (0.20 - 0.60)*** 0.27 (0.15 - 0.48)*** 
Bipolar affective disorder 8 (40.0) 0.31 (0.13 - 0.76)* 0.37 (0.15 - 0.94)* 0.35 (0.14 - 0.90)* 11 (55.0) 0.37 (0.15 - 0.90)* 0.49 (0.18 - 1.26) 0.41 (0.16 - 1.09) 
Other non-organic 
psychoses 
8 (61.5) 0.74 (0.24 - 2.27) 0.78 (0.25 - 2.42) 0.75 (0.24 - 2.33) 12 (92.3) 3.66 (0.48 - 28.2) 3.81 (0.49 - 29.4) 3.44 (0.44 - 26.7) 
Depot injectable 
 
       No 42 (56.8) 0.61 (0.38 - 0.97)* 0.58 (0.36 - 0.96)* 0.56 (0.34 - 0.92)* 48 (64.9) 0.56 (0.35 - 0.91)* 0.49 (0.29 - 0.81)** 0.43 (0.26 - 0.72)*** 
Yes 11 (36.7) 0.27 (0.13 - 0.57)*** 0.26 (0.12 - 0.60)** 0.22 (0.09 - 0.52)*** 18 (60.0) 0.46 (0.22 - 0.95)* 0.41 (0.18 - 0.91)* 0.32 (0.14 - 0.72)** 
Typical antipsychotic 
        
No 28 (50.9) 0.48 (0.28 - 0.82)** 0.50 (0.28 - 0.89)* 0.49 (0.27 - 0.86)* 34 (61.8) 0.49 (0.29 - 0.85)* 0.42 (0.23 - 0.75)** 0.37 (0.21 - 0.67)*** 
Yes 25 (51.0) 0.48 (0.27 - 0.85)* 0.44 (0.24 - 0.81)** 0.39 (0.21 - 0.73)** 32 (65.3) 0.57 (0.32 - 1.03) 0.52 (0.28 - 0.97)* 0.42 (0.22 - 0.80)** 
Atypical antipsychotic 
 
       No 8 (87.1) 0.62 (0.21 - 1.78) 0.59 (0.20 - 1.71) 0.54 (0.18 - 1.58) 8 (57.1) 0.41 (0.14 - 1.18) 0.41 (0.14 - 1.20) 0.32 (0.10 - 0.96)* 
Yes 45 (50.0) 0.46 (0.31 - 0.70)*** 0.45 (0.29 - 0.71)*** 0.43 (0.27 - 0.67)*** 58 (64.4) 0.55 (0.36 - 0.86)** 0.47 (0.30 - 0.76)** 0.41 (0.26 - 0.66)*** 
Any indicator of severity1 
 
       No 45 (57.0) 0.61 (0.39 - 0.96)* 0.56 (0.35 - 0.91)* 0.54 (0.33 - 0.87)* 56 (70.9) 0.74 (0.46 - 1.21) 0.61 (0.37 - 1.01) 0.52 (0.31 - 0.87)* 
Yes 23 (46.0) 0.39 (0.23 - 0.69)*** 0.43 (0.24 - 0.77)** 0.39 (0.21 - 0.71)** 27 (54.0) 0.36 (0.20 - 0.63)*** 0.37 (0.20 - 0.66)*** 0.31 (0.17 - 0.56)*** 
Any indicator of risk2 
 
       No 54 (59.3) 0.68 (0.44 - 1.03) 0.64 (0.41 - 1.00) 0.61 (0.39 - 0.96)* 64 (70.3) 0.72 (0.46 - 1.14) 0.65 (0.40 - 1.04) 0.56 (0.35 - 0.91)* 
Yes 14 (36.8) 0.27 (0.14 - 0.52)*** 0.28 (0.14 - 0.57)*** 0.25 (0.12 - 0.51)*** 19 (50.0) 0.31 (0.16 - 0.58)*** 0.27 (0.14 - 0.54)*** 0.22 (0.11 - 0.44)*** 
